Market Newsdesk

MONTREAL, April 19, 2021 (GLOBE NEWSWIRE) — (TSX-V:GKO) – Geekco Technologies Corporation announces a partnership with the favorite and well-known non-profit organization BIXI Montréal. Geekco and the Montreal bike-sharing service are joining forces via the FlipNpik application to promote local businesses. This is great news, especially for BIXI users and members! All they have to do is download the FlipNpik application and actively promote local businesses to benefit from exclusive promotions, including those offered by BIXI in the FlipNpik application’s surprise box.

A NATURAL FIT

BIXI’s collaboration encourages and rewards the local community which actively promotes neighbourhood businesses. Just like FlipNpik, it acts as a change agent regarding the environment and the local economy. BIXI continually seeks to contribute to improving the urban experience, using an innovative, accessible and collaborative system. Rewarding and encouraging the community to discover and promote neighbourhood businesses on the FlipNpik app while commuting on BIXI is an example of stimulating the local economy through synergy.

“The partnership with Geekco was a natural fit. We understand the importance of the vitality and viability of local businesses in our city. It is a great privilege for us to actively contribute to the FlipNpik system and to participate in helping the merchants of the greater Montreal area who have been hit hard by the pandemic. This collaboration allows us to offer our users and members an additional incentive to discover their city by bike,” says Christian Vermette, BIXI Montréal’s General Manager.

TOGETHER DURING A PANDEMIC

“Joining forces in the wake of this devastating pandemic crisis to better support the local economy is fundamental. As a partner, BIXI will feed our surprise box with monthly subscriptions and discounts to motivate and reward users who post on FlipNpik and boost local merchants’ visibility in the greater Montreal area,” explains Erik Giasson, CEO of Geekco.

ABOUT GEEKCO
Geekco is at the forefront of social media with FlipNpik, a collaborative social media app where the community shares local experiences. The mobile application unites and rewards consumers, content creators, and media influencers who promote local businesses and buying locally. Users sharing digital content on FlipNpik collect Flip social points they can exchange for exclusive products or services from strategic partners and registered local businesses in the application’s surprise box.

ABOUT BIXI

Launched in 2014 by the city of Montreal, BIXI Montréal is a bike-sharing non-profit organization. More than 8,000 bikes and 600 bike stations are available in the greater Montreal area including Laval, Longueuil, Westmount, Town of Mount Royal, and Montreal East. More than just a means of transportation, BIXI is a great way to zip around the city whenever and wherever you want.

BIXI’s bike-sharing popularity is ever-growing, with a record 5.8 million rides logged before the pandemic – an 8% increase over 2018. Nearly 320,000 users choose BIXI.

Media Contact:

BROUILLARD | [email protected] | 418 682-6111

Geekco Technologies Corporation

Erik Giasson, CEO | 514 919-0451

Nadira Hajjar, President | 514 993-6239

BIXI Montréal

Customer Service | [email protected] | 514 789-BIXI (2494)

Neither TSX Venture Exchange nor its regulation services provider (as such term is defined in the TSX Venture Exchange’s policies) accept responsibility for the relevance or accuracy of this press release.

SAN JUAN, April 19, 2021 (GLOBE NEWSWIRE) — BOTS, Inc. (OTC: BTZI), a vertical integrator and an emerging innovator of products, technologies, and services for the rapidly growing digital robotics automation, cybersecurity, and manufacturing industry, announced today that it entered into an agreement to acquire 50% ownership of Beadswap (in beta) from Equity Art Corp.

The purchase includes 50% ownership in a related 8.1 trillion beadswap coins (CRYPTO: BEAD) generated on the Ethereum blockchain and listed on Beadswap as seen here: https://info.beadswap.me/#/home

“We were attracted to the carefully designed Beadswap knowing that similar decentralized exchanges such as Uniswap enjoy a market cap of more than 10 billion USD with smaller upstart competitors to Uniswap quickly reaching more than 1 billion in market cap after launching as well as the magnitude of the seller’s assets and operational magnitude,” stated Bots’ Chairman, Simon Rubin.

A recent article published by Forbes.com entitled Coinbase, Kraken, Gemini, And Other Crypto Exchanges Must Embrace Defi To Capture Growth –described the following: “Coinbase’s direct listing on Nasdaq is a watershed moment for the crypto industry. It will be the first public crypto company with pure and dependable cash flows that are on par with some of the largest and most established exchanges in the world. Coinbase generated 2020 revenue of $1.3 billion, compared to CBOE’s $1.2 billion, Nasdaq’s $2.9 billion, and CME’s $4.9 billion. Despite launching a myriad of products such as Commerce (SPSC ), Earn, Custody, staking, and others, trading fees make up the lion’s share of Coinbase’s $3.4 billion LTD revenue, at approximately 96%. DEXs are a type of crypto exchange within the decentralized finance (“Defi”) ecosystem that allows for direct peer-to-peer transactions to take place without intermediaries. By utilizing decentralized smart contracts encoded on public blockchains, users always retain their private keys, which removes counterparty risk inherent to centralized exchanges. Defi offers a fast-growing ecosystem of continuous innovation as distributed project teams interact with open-source protocols and create novel use cases previously unimaginable. In order to be competitive and retain market share, centralized exchanges must form mutually beneficial symbiotic relationships with Defi platforms and products.

“DEXs” such as Uniswap, Sushiswap, 0x, Curve, Serum, Balancer, and others combined monthly volume surpassed $61 billion in January of this year. Six months prior, in July 2020, the combined DEX monthly volume was just $4.9 billion, an astounding increase of over 1,100%. Although the combined volume of centralized exchanges in January was considerably higher at $906 billion, DEX volume is catching up with a current volume ratio of 7%, up from 4.6% in July of last year.

“Coinbase, Kraken, Gemini, and other exchanges are thriving, but what will happen if decentralized exchanges (“DEXs”) continue their spectacular growth, fundamentally threatening to disrupt their centralized counterparts?”

In unrelated news, Bots expects to file its 10K later today and plans to provide an additional update when it reports its full third-quarter results later this month.

About Equity Art Corporation

Equity Art Corp., founded in 2004, is a large-scale enterprise specializing in asset collection, art trade, product development, and tourism. Headquartered in Xi’an, China, the Company’s business philosophy is inspired by the history and culture of the ancient Silk Road.

Equity Art’s flagship property is the Silk Route Museum, one of the largest privately-owned museums in China. It features a construction area of over 10,000 square meters and contains an international collection of over 35,000 works of fine art, historical artifacts, fossils, and jade masterpieces. The Company’s other projects include one of the world’s largest subterranean art galleries, the Dunhuang Natural History museum, a 700-acre Silk Road tourism and expo center, an art auction business, and the online travel platform Silkroad.host.

Recognizing the unique opportunity presented by blockchain to provide more reliable provenance tracking for art and antiques, the Company in 2018 created Equity Art Online; a digital division focused on utilizing distributed ledger technology, 3D scanning, and non-fungible tokens (NFT) to advance the art and museum industries. Beadswap, a decentralized asset exchange, is one of the core components of this initiative.

About Beadswap

Beadswap.me is a decentralized exchange built on the Ethereum network. Users can swap, create markets, add liquidity, and stake Ethereum-based tokens without the use of an intermediary. Unlike traditional, centralized market-making, Beadswap uses an automated market maker (AMM) protocol to facilitate decentralized trading so that prices are determined algorithmically instead of through an order book. Shang He, Vice President of Equity Art Online, commented, “The total value locked in Defi platforms grew from around $1 billion a year ago to over $60 billion currently. We are excited to bring this groundbreaking new technology to help revolutionize the art and tourism sectors.”

About BOTS, Inc.

Headquartered in San Juan, Puerto Rico, BOTS, Inc. – publicly traded on the OTC Markets under the symbol (BTZI) is a diversified company developing and servicing blockchain, cybersecurity, and robotics solutions for its clientele. The Company is committed to driving the innovations needed to shape the future of digital robotic automation management through digital technology and decentralized blockchain solutions. Management is dedicated to the strong growth of Distributed Asset Technology and Robotic Process Automation (RPA).

Shareholders, potential investors, and others should note that we announce material events and material financial information to our shareholders and the public using our website and the social media addresses listed below, as well as in our SEC filings, press releases, public conference calls, and webcasts. We also use social media to communicate with our subscribers and the public about our Company, services, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage shareholders, the media, and others interested in our Company to review the information we post on the U.S. social media channels listed below. This list may be updated from time to time.

Track BTZI news on Facebook @ https://www.facebook.com/Bots.Bz/

Follow BTZI news on Twitter @Bots_bz http://www.Twitter.com/Bots_bz

Find BTZI news at http://www.bots.bz

Bots, Inc. has been featured in media nationwide, including CNBC, Bloomberg, TheStreet.com.

For more information, visit http://www.bots.bz

Visit BTZI on Facebook

https://www.facebook.com/Bots.Bz/

Follow BTZI on Twitter @Bots_bz

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as may be disclosed in the Company’s filings. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release. Such forward-looking statements are risks that are detailed in the Company’s website and filings.

Contact:

Paul Rosenberg

CEO

[email protected]

NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) — SPARBAR, INC., (“Company”) the North American distributor and IP licensee of the U.K.-created SPARBAR^®-branded boxing fitness equipment, is proudly introducing their new generation of exceptional combat talents.

Two of them being only 5 years old, these mini fighters cause a buzz in their communities. SPARBAR^® brand founder and CEO Jasvinder “Jazz” Gill says: “Those kids are just on a different level. They are destined to be champions, and we are proud to be part of their story.”

To support the SPARBAR^® kids & youth talents, the Company brand provides them not only with innovative training equipment; each talented youth athlete’s guardian receives shares in the Company – in their name – in trust for their future.

See here 12 future superstars to watch out for:

            1)   Prince ‘The Buzz’ Larbie (age 8)

There’s a strong force coming from Ghana, Africa. More precisely, from Ghana’s hometown of boxing champions, Bukom in Jamestown “I’m from a small community called Jamestown. In Jamestown, we have two choices in life. Football or boxing. A boxer is what I’ve become,” says 8 years old Prince ‘The Buzz’ Larbie, who was voted 2020 Best Juvenile Boxer by the Boxing Writers Association Ghana. 

Prince has been immersed into boxing with his dad being a boxing coach and former pro boxer. His hometown of Bukom is only the size of 2 soccer fields, packed with 40 boxing gyms and has produced 6 world boxing champions. Boxing may very well be in Prince’s DNA, but his boxing IQ and sparring skills are at a next-level. A BBC documentary about Prince went viral, and he does not only have the whole nation of Africa behind him, but the international community and team of the SPARBAR^® brand.

            2)   Caden ‘The Tornado’ James (age 5)

This speedy boxer from the UK known as “The Tornado“ got discovered by SPARBAR^® founder Jazz on Instagram: “We got excited seeing this power and technique at the tender age of 5.”

Caden is known in his home town Sheffield for his 7 world records, largely given for the speed of his punches. He is now trained by Olympic medallists and World Boxing Champions such as Robin Reid out of Manchester, and became one of the youngest Brand Ambassadors at SPARBAR^®.

            3)   Jayden ‘The Predator’ Price (age 9)

9-year-old Jayden ‘The Predator’ Price used to be quiet in school, and his mum wanted to build up his confidence by sending him to a Brazilian jiu-jitsu course. The great talent now ranks no 1 in BJJ in the UK, earning two World Champion and three National Champion titles. His love for combat sports quickly extended to boxing and MMA, and Jaden was a natural on the SPARBAR^® Pro right away.

            4)   Rianna ‘Tank’ Doforo (age 13)

13 year old Rianna ‘Tank’ Doforo from Liverpool, UK, has always been a very athletic, powerful kid. She found her passion in sparring, and now dedicates 9 training sessions per week into boxing. “Her confidence and self-belief have gone through the roof when she picked up boxing,” her parents say about her training.

With the SPARBAR^® Pro, she continuously improves her hand speed and reflexes. Rianna trained at the Mayweather gym in Vegas and was chosen a Junior Ambassador by WBC (World Boxing Council) for not only performing outstanding boxing skills, but using her voice for anti bullying and kindness.

            5)   ‘Lethal’ Lilly-May (age 17)

A force to be reckoned with, 17 year old British ‘Lethal’ Lilly-May started boxing when she was 9 to build her self-confidence after having to go through bullying at school. Now she trains 6 days a week at a sports college, has won a national title, and is simply loving her life working towards her goals to become a professional boxer, undisputed champion and go to the Olympics.

            6)   Cee-Jay Sheelan (age 9)

9 years old Irish Cee-Jay Sheelan is into all of the Martial Arts since he was 4. At only 5 years old, he started competing nationally and internationally. “He always wanted to fight,” his dad recalls. Cee-Jay won the Irish Kickboxing national title twice at 2 different weight classes, and now added MMA to his training program. He sees the SPARBAR^® Pro as his “gaming console”.

            7)   Klayton Bonas (age 5)

At the age of 3, Klayton’s dad got him a pair of gloves and pads to mess around with in the house, and li’l Klayton did not stop boxing a day ever since. UK boxing gyms made an exception on their membership age-restrictions and asked to bring in now 5 year old Klayton Bonas when they saw his natural ability in social media videos. Klayton loves sparring, and SPARBAR^® boxing fitness equipment gives his dad a break. After their daily sessions, Klayton loves to watch his heroes Floyd Mayweather, Ryan Garcia and Paquiao.

            8)   Jaya AKA Jayweather (age 11)

Youth athlete Jaya AKA Jayweather started boxing at the age of 7. Growing up Jaya was more interested in Power Rangers than barbie dolls. At the age of 6 Jaya started Karate, and with her dad’s love of the boxing sport was encouraged to start boxing. From the moment she first walked through the boxing gym doors her boxing coach saw great potential in her. From being a shy little girl Jaya walked into a boxing gym full of men and made to feel a part of the family. Now filled with confidence, Jaya has already competed in 3 fights. This girl has the drive and dedication to go far and reach her dreams of winning gold medals and belts.

            9)   Serena Mali (age 11) 

11-year-old fighter Serena Mali got discovered by the SPARBAR^® team from articles and posts her head coach released to tell the UK about her abilities. Being one of two girls in the local boxing gym, her head coach reports she is “showing the mentality, character and skill-set needed to be a top boxer.” Serena has always been on the athletic side, trying out every sort of sport before she dedicated herself into boxing. She now trains 5 times a week towards her goal to become a pro boxer and to go to the Olympics. 

            10)   Nicholas Lecointe-Akore (age 16)

UK-based Nicholas Lecointe-Akore got into Brazilian jiu-jitsu for a year, and won Gold in the BJJ English Open Championships when he was 13. He swapped to boxing right afterwards, and now his coaches prepare the now 16-year-old to become a National Champ and a Junior Olympian. Nicholas loves sparring. His father, a martial artist and boxing coach himself, reports: “He’s determined when he fights.”

            11)   Tyler James “Taekwondo Kid” (age 9)

“Taekwondo Kid” Tyler James kicks the SPARBAR^® seven days a week because he knows he’s soon going to rock the Olympics in Taekwondo. He started taking lessons as a 4-year-old and just never stopped training, taking home a 2019 National Champion title and being #1 in Taekwondo in his home country the U.S. in his age and weight group. “The sport has boosted his confidence, and he’s not afraid to talk to people like he used to,” his father reports. Taekwondo also helped Tyler keep his mind busy as he coped with the loss of his mother at age 6. Great kicks come with great style: Tyler’s hair comes in different colors on TikTok and Instagram. “A mohawk we do with coloring hair wax that you can wash out,” his father lets us know. 

            12)   Jasmine Paul (age 9)

A kickboxer, tennis player, runner, and overall athlete, Jasmine enjoys all sorts of sports since she could walk, and started collecting medals and awards for her outstanding athletic performances from the age of 3. Coming from an active family, her biggest cheerleader is her sister Roxanna, 4, who now joins her on her 6 days a week training sessions.

When she’s not on long-distance running tracks, perfecting her tennis game, or competing in kickboxing all over the UK, she’s kicking and punching the SPARBAR^® Pro in her home gym together with her family. Her first contact with the brand was at a SPARBAR^® Kids Ambassador Day in the UK, where she was inspired by meeting other super sporty kids and teens.

Jazz about the SPARBAR^® talents: “Our talent scouting is truly social-driven. Many fighters come from a tough background. We aim to support kids that choose boxing and sports to overcome adversity, and get the most out their life.“ The SPARBAR^® team hosts global Ambassador days, where the junior talents meet World Champions.

The original SPARBAR

^®

products are available at sparbar.com and at retailers listed at this website.

ABOUT SPARBAR

^®

– THE WORLD FAMOUS SPARRING PARTNER:

A global sports fitness brand, SPARBAR^® is proud of its position as the inventors of the global combat sensation that known the world over as SPARBAR^® Pro. Founded in 2013 and backed by over 20 years of real boxing experience, we have single-handedly changed the fight game with our innovative concept of training without a sparring partner.

Used by world champions, international celebrities, world-leading gyms and with over 300M+ social media video views, the SPARBAR^® success ensures that we are not just pioneers, but game-changers in the combat sports training equipment market. SPARBAR^® is the key to learning core fundamental boxing skills and developing hand-eye coordination as you build footwork, balance, speed, stamina, accuracy and power, simulating realistic sparring in a safe environment.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy, product development and potential success, as well as technological and/or other factors and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, and financial. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our dependence on third-party suppliers and partners; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks. Important factors that may cause the actual results to differ from those expressed within may include but are not limited to: the success or failure of SparBar’s efforts to successfully market its fitness and sports brand products and services; SparBar’s ability to attract and retain quality employees; the effect of changing economic conditions; increased competition; the ability of Sparbar to obtain adequate equity financing. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

More at sparbar.com

Instagram @sparbarboxing
YouTube Sparbar Boxing

Company contact:

SPARBAR Inc.
7 Penn Plaza Suite 420
New York, NY 10001
Email: [email protected]
Tel: +1 800-803-6645

Press contact:

Melanie Marten, The Coup
[email protected]
+49 1707308126

SOURCE: Sparbar Inc.

Related Links

http://www.sparbar.com

Attachment

• SPARBAR® Prince ‘The Buzz’ Larbie 2

GRAPEVINE, Texas, April 19, 2021 (GLOBE NEWSWIRE) — GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today announced that George Sherman will be stepping down as Chief Executive Officer on July 31, 2021, or earlier upon the appointment of a successor. The Board of Directors (the “Board”) thanks Mr. Sherman for his significant contributions since being appointed Chief Executive Officer in April 2019.   

As disclosed in GameStop’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 23, 2021, the Board has been evaluating executive leadership to ensure the Company has the right skills to meet changing business requirements. The Company’s Form 10-K also noted that the Board has retained a third-party firm to support its efforts. The Board’s Strategic Planning and Capital Allocation Committee is leading a search to identify Chief Executive Officer candidates with the capabilities and experience to help accelerate the next phase of the Company’s transformation.

Ryan Cohen, incoming Chairman of the Board, commented, “GameStop appreciates the valuable leadership that George has provided throughout his tenure. He took many decisive steps to stabilize the business during challenging times. The Company is much stronger today than when he joined. On a personal note, I also want to thank George for forming important partnerships with the new directors and executives who have joined GameStop in recent months.”

George Sherman, Chief Executive Officer, added, “I am very proud of what we have accomplished at GameStop over the past two years, including during the difficult COVID-19 pandemic. It has been a privilege to lead so many dedicated, talented individuals, who collectively possess tremendous passion for the gaming industry. We have helped bring stability and strength to the business, including by de-densifying our store footprint, reducing costs and debt, and driving e-commerce growth. I also want to take this opportunity to thank our Board for all of its collaboration and support.”

About GameStop.

GameStop, a Fortune 500 company headquartered in Grapevine, Texas, is a leading specialty retailer offering games and entertainment products through its E-Commerce properties and thousands of stores. Visit www.GameStop.com to explore our products and offerings. Follow @GameStop and @GameStopCorp on Twitter and find us on Facebook at www.facebook.com/GameStop.

Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor

This press release contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally  include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the SEC including, but not limited to, the Company’s Annual Report on Form 10-K for the fiscal year ended January 30, 2021, filed with the SEC on March 23, 2021.  All such filings are available at www.sec.gov and on the Company’s website at www.GameStop.com.

Contact

GameStop Investor Relations
817-424-2001
[email protected]

GameStop Public Relations
Joey Mooring
[email protected]

or

Profile
Greg Marose / Charlotte Kiaie
[email protected]

 

VANCOUVER, British Columbia, April 19, 2021 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis, today announced that it has signed a Cannabis Purchase and Sale Agreement (the “Agreement”) with the Yukon Liquor Corporation for the distribution of its portfolio of cannabis products to consumers in Yukon territory.

The Company has received its first purchase order and is expecting to make its first shipment under the Agreement in April 2021. Simply Bare^TM Organic super-premium flower will now be available in stores and online in seven provinces and territories, representing more than 90% of the Canadian population.

“Simply Bare^TM Organic will now be heading due north to our friends and partners in the Yukon territory, expanding Rubicon Organics’ geographic coverage across Canada. As we build on our vision of developing a global premium cannabis brand, each step towards reaching new consumers is very valuable to our organization,” said Jesse McConnell, Chief Executive Officer.

Grant of Restricted Share Units & Options

The Company has granted an aggregate of 2,540,000 restricted share units (“RSUs”) in accordance with the Company’s equity incentive plan to certain executives of the Company as compensation for their services. The vesting conditions of the RSUs are as follows: (i) 350,000 vesting between one and three years from the date of grant; and (ii) 2,190,000 vesting in tranches based on 12-month EBITDA targets.

In addition, the Company also granted 79,000 stock options to certain employees of the Company pursuant to the equity incentive plan. The stock options are exercisable at $3.25 per share for a period of five years from the date of grant.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics Inc. is becoming the global brand leader in organic cannabis products. Through its wholly owned subsidiary Rubicon Holdings Corp, a licensed producer, the Company cultivates, processes and sells organic certified, sustainably produced, super-premium cannabis products from its state-of-the-art hybrid greenhouse located in Delta, BC, Canada. Rubicon Organics is focused on achieving industry leading profitability through a focus on innovation and the development of brands and cannabis 2.0 products, including its flagship super-premium brand Simply Bare^TM Organic and its super-premium concentrate brand LAB THEORY^TM.

CONTACT INFORMATION

Margaret Brodie
Chief Financial Officer
Phone: +1 (437) 929-1964
Email: [email protected]

The TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, and statements such as the expected first shipment date to the Yukon Liquor Corporation, and the Company’s intention of achieving industry leading profitability are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will” or variations of such words or statements that certain actions, events or results “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that its capital needs will be as currently projected. Risks and uncertainties associated with forward looking information in this press release include, among others, information or statements concerning the Company’s expectations of financial resources available to fund operations; Rubicon Organics’ limited operating history and lack of historical profits; obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the Company’s ability to obtain financing at reasonable terms through the sale of equity and/or debt commitments; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; that our current relationships with our suppliers, service providers and other third parties will be maintained; and the impact of the current global health crisis caused by the COVID-19 pandemic. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Although Rubicon Organics has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

CytoDyn is following all patients treated with leronlimab under CSP and will provide additional information when available and authorized for release

VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today former President of the Philippines, Joseph Estrada, was administered leronlimab under Compassionate Special Permit (CSP), among other medication, as a therapeutic for COVID-19. Mr. Estrada remains hospitalized and news reports indicate he may be transferred from ICU to a regular hospital room soon. CytoDyn continues to ship vials of leronlimab to the Philippines, while its distribution partner, Chiral Pharma Corporation, works closely with the Philippine FDA to consider expanding the CSP.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We have been working with Chiral Pharma for several months to provide COVID-19 patients in the Philippines access to leronlimab under CSP. CytoDyn is grateful for the opportunity to help the former President and his family and we wish him a full and speedy recovery. While we pursue emergency use authorizations in many countries and initiate final trials for the severe and critical COVID-19 patient populations to strengthen these applications, our teams remain hopeful their dedication and efforts will help COVID-19 patients around the world. We also are happy to report our BLA resubmission for HIV is on track and we are encouraged with the advancements in our expanding cancer program. I look forward to providing a full update to all of our stakeholders soon.”

About Leronlimab (PRO 140)

The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat HIV and metastatic cancer. The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor important in HIV infection, tumor metastases, and other diseases, including NASH (nonalcoholic steatohepatitis). Leronlimab has been studied in 11 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients). 

Leronlimab is a viral-entry inhibitor in HIV/AIDS. It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent with fewer side effects and less frequent dosing requirements than currently used daily drug therapies. 

Cancer research has shown CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. As a result, CytoDyn is conducting two Phase 2 human clinical trials, one in mTNBC, which was granted Fast Track designation by the FDA in 2019, and a second in a basket trial which encompasses 22 different solid tumor cancers.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. After completing two clinical trials with COVID-19 patients (a Phase 2 and a Phase 3), CytoDyn initiated a Phase 2 investigative trial for post-acute sequelae of SARS COV-2 (PASC), also known as COVID-19 Long-Haulers. This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC. It is currently estimated that between 10-30% of those infected with COVID-19 develop long-term sequelae. Common symptoms include fatigue, cognitive impairment, sleep disorders, and shortness of breath. If this trial is successful, CytoDyn plans to pursue clinical trials to evaluate leronlimab’s effect on immunological dysregulation in other post-viral syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis. Preclinical studies revealed a significant reduction in NAFLD and a reduction in liver fibrosis using leronlimab. There are currently no FDA approved treatments for NASH. NASH is a leading cause of liver transplant. About 30 to 40 percent of adults in the U.S. live with NAFLD, and 3 to 12 percent of adults in the U.S. live with NASH.

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has been working diligently to refile its Biologics License Application (“BLA”) for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing. CytoDyn expects to refile its BLA in the first half of the calendar year 2021 or shortly thereafter.

CytoDyn also completed a Phase 3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension approval. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce the viral burden in people infected with HIV. Moreover, a Phase 2 clinical trial demonstrated that leronlimab monotherapy could prevent viral escape in HIV-infected patients; several patients on leronlimab’s Phase 2 monotherapy extension arm have remained virally suppressed for more than six years. There have been no strong safety signals identified in patients administered leronlimab in multiple disease spectrums, including patients with HIV, COVID-19 and Oncology.

CytoDyn is also conducting a Phase 2 clinical trial with leronlimab in mTNBC, a Phase 2 basket trial in solid tumor cancers (22 different cancer indications), Phase 2 investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 Long-Haulers, and a Phase 2 clinical trial for NASH. CytoDyn has already completed two trial in COVID-19 patients (a Phase 2 and a Phase 3) and is in the process of conducting an additional COVID-19 Phase 3 trial for mechanically ventilated critically ill COVID-19 patients. More information is at www.cytodyn.com. 

Forward-Looking Statements 

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTS

Investors:

Michael Mulholland
Office: 360.980.8524, ext. 102
[email protected]

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the initiation of dosing in a Phase 2 proof-of-concept trial in patients with head and neck squamous cell carcinoma (HNSCC). The trial will assess the efficacy and safety of vidutolimod (CMP-001) in combination with pembrolizumab for the treatment of patients with first-line relapsed or metastatic HNSCC. The results of this trial are expected in the 2nd half of 2022, with initial data in a subset of patients anticipated before the end of 2021.

“The initiation of patient dosing in this head and neck cancer trial is an important milestone for our indication-expansion strategy for vidutolimod,” said Barry Labinger, President and Chief Executive Officer of Checkmate. “Fewer than 20% of patients with relapsed or metastatic HNSCC respond to single-agent checkpoint blockade, which highlights the substantial need for a chemotherapy-free regimen with an improved rate and duration of response.”

Checkmate is also conducting two clinical trials of vidutolimod in combination with nivolumab in the lead indication of melanoma. The first is a Phase 2 trial assessing the efficacy and safety of vidutolimod in combination with nivolumab for the treatment of patients with anti-PD-1 refractory melanoma. The second is a Phase 2/3 trial comparing the efficacy and safety of vidutolimod in combination with nivolumab to nivolumab monotherapy in patients with first-line metastatic or unresectable melanoma. Checkmate previously announced initiation of patient dosing in the first-line melanoma trial in March 2021. Trial sites have been activated and patient screening is underway in the refractory melanoma study. 

Additional information about Checkmate’s HNSCC trial, including participating investigative sites, can be found here: https://clinicaltrials.gov/ct2/show/NCT04633278.

Information about the Phase 2 anti-PD-1 refractory melanoma trial and the Phase 2/3 melanoma study can be found here: https://checkmatepharma.com/pipeline/clinical-trials/.

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com.

Availability of Other Information About Checkmate Pharmaceuticals

Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward Looking Statements

Various statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data; and expectations regarding the timing, initiation, implementation and success of its planned and ongoing clinical trials for CMP-001, and the benefits and related implications of current and future partnerships and/or collaborations. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the results from clinical trials, including the fact that positive results from a trial may not necessarily be predictive of the results of future or ongoing clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act 1933, as amended, which is available on the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in Checkmate’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Checkmate undertakes no duty to update this information unless required by law.

Investor Contact
Rob Dolski
Chief Financial Officer
[email protected]

Media Contact
Karen Sharma
MacDougall
781-235-3060
[email protected]

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., April 19, 2021 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today in the development of Tyvaso DPI^™ as United Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA).

“The NDA submitted today by United Therapeutics builds upon a drug master file previously submitted by MannKind,” said Michael Castagna, CEO of MannKind Corporation. “We are excited to see the second compound formulated with our technology complete a rigorous clinical development program. If approved by the FDA, Tyvaso DPI is expected to provide a major advancement in the delivery of inhaled treprostinil for PAH and PH-ILD patients.”

MannKind and United Therapeutics entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development and commercialization of Tyvaso DPI, a dry powder formulation of treprostinil, delivered via a small, portable dry powder inhaler. Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat^® inhalation device technology used in MannKind’s Afrezza^® (insulin human) Inhalation Powder, which was approved by the FDA in 2014.

Tyvaso DPI, if approved, is expected to provide a convenient choice of inhaled administration for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). There are approximately 45,000 treated PAH patients in the U.S. and United Therapeutics estimates at least 30,000 treatable PH-ILD patients in the U.S.

United Therapeutics has applied a priority review voucher to the NDA that could provide for an FDA decision by December 2021. The FDA must first accept the application for review and issue a formal decision date in accordance with the Prescription Drug User Fee Act.

MannKind and United Therapeutics are also developing BluHale^®, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help the patient track information about inhaler use.

Tyvaso DPI is an investigational therapy that is not approved for any use in any country or indication and the Tyvaso DPI tradename is pending final FDA review.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza^® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra-rapid-acting mealtime insulin in the United States, where it is available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif. with a state-of-the-art manufacturing facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Forward-looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind’s expected use of proceeds from the offering. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties regarding the regulatory approval process, and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

TYVASO is a registered trademark of United Therapeutics Corporation.

TYVASO DPI is a trademark of United Therapeutics Corporation.

AFREZZA, BLUHALE, TECHNOSPHERE and DREAMBOAT are registered trademarks of MannKind Corporation.

CONTACTS:

For MannKind:	For United Therapeutics:
Christie Iacangelo, Corporate Communications	Dewey Steadman, Investor Relations
(818) 292-3500	(202) 919-4097
Email: [email protected]	Email: [email protected]

Rose Alinaya, Investor Relations
(818) 661-5000
Email: [email protected]

TEL AVIV, Israel, April 19, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today provided an update of recent corporate developments.

• Shareholders approved a 1:15 reverse stock split, reducing the number of outstanding shares from 118 million to 7.9 million shares, which will take effect following the close of trading on April 26, 2021
• Today, the Company submitted its application to join the Nasdaq Capital Market, which the Company views as more attractive to a broader range of investors than its current listing

InspireMD CEO Marvin Slosman commented, “The fundamentals of our business remain sound and consistent and, as previously noted, our execution against our milestones continues to progress well. Following our previously announced oversubscribed capital raise of $20.7M we are securely positioned to conduct our C-Guardian FDA clinical trial while maintaining sufficient operating capital to meet our commercial expansion and product development goals, while establishing CGuard EPS as the most advanced carotid stent system in the market. Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease. We believe that moving to the Nasdaq Capital Market is a strategically sound approach that places us in the company of our peers and allows for improved visibility in the market. InspireMD is fundamentally a stronger company today than ever before, and I am proud of the extraordinary efforts of our expanding team in creating an exciting future for our company.”

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.

InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain of its warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
[email protected]

CORE IR
[email protected]

• Camping equipment purchases are projected to grow 30% over the next 5 years, with some companies currently seeing 200% more demand for their products.
• The Dyrt PRO, the top camping app, is on track to grow 400% in 2021.

PORTLAND, Ore., April 19, 2021 (GLOBE NEWSWIRE) — Today, top camping app The Dyrt PRO confirmed that it has entered into partnerships with over 70 outdoor companies already this year to combine forces and meet the growing demand for camping.

Increasing interest in outdoor activities has put a spotlight on the need for campground information. The Dyrt PRO, with over 1 million+ campsites, reviews, and tips, addresses that need, and outdoor companies can now offer that value to their customers.

Customers of these 70 companies can now get free memberships to The Dyrt PRO, The Dyrt’s quickly growing premium membership. In return, The Dyrt will feature some of these companies in The Dyrt Magazine, and some as prizes in The Dyrt’s Campground Review Contests, which fuel their crowd-sourced campground review platform.

“From day one our focus has been on building the biggest camping community. Community allows us to provide the best camping information from the most trusted source — other campers,” explained Kevin Long, CEO of The Dyrt. “Increasing that information flow, with help from our new outdoor partner companies, will now make going camping even easier.”

The 70+ companies see the relationship as mutually beneficial as well.

“As a company, we strive to not only fill the needs addressed by our products, but to also improve overall outdoor experiences,” says Andrew Kinsman from Midland Radio Corporation. “Giving our customers The Dyrt PRO does just that.”

Customers of these 70+ companies will automatically receive free 90-day memberships to The Dyrt PRO with any purchase, effective immediately:

686, A Cajun Life, Action Heat/The Warming Store, AIYRE, Alpine Start, Amazing RVs, Banner & Oak, Basecamper, Boost Oxygen, Boulder Denim, CampFare, Capitol Hill Outfitters, CloudLine, Crazy Creek, Cruise America, CS Coffee, Cusa Tea & Coffee, Eddie Bauer, Four Points, Full Windsor, Good To-Go, GourmetNut, Gravel Travel, GrowlerWerks, Hammock Bliss, Hammock Gear, Heroclip, Hollywood Racks, Hybrid Light, Kalahari, Kelty, Kovr Sunscreen, Life in Tents, Liquid IV, LivBar, Marie Originals, Midland Radio Corporation, Native Camper Vans, Ncamp, NW Alpine, Out Van About, Outdoor Element, Outdoor Tech, Peace Vans, Pladra, Point6, Raw Rev, RedLedge, Shamma Sandals, Sierra Designs, SockGuy, Speedy Blaze, Supernola, Texas RV Rental, This American VanLife, Titus, TrailTopia, Travellers Autobarn, Tru Flask, US RV Adventure, Vintage Surfari Wagons, Wandervans PNW, Wandervans.com, Wandrd, Watershed, Wenzel, Wigwam, Wraptie.

About:

The Dyrt PRO
With over 1 million+ campsites, reviews, and tips, The Dyrt PRO offers the most comprehensive campground search features and camping discounts. Available on the web, iOS, and Android.

Sources: Camping equipment sales growth: https://www.forbes.com/sites/timnewcomb/2020/12/09/small-and-mid-size-outdoor-companies-see-quick-growth-face-major-decisions-amidst-pandemic/

Press Contact: Maggie Fisher [email protected]